Literature DB >> 29444326

Data maturity and follow-up in time-to-event analyses.

Val Gebski1, Valérie Garès1, Emma Gibbs1, Karen Byth1.   

Abstract

We propose methods to determine the minimum number of subjects remaining at risk after which Kaplan-Meier survival plots for time-to-event outcomes should be curtailed, as, once the number remaining at risk drops below this minimum, the survival estimates are no longer meaningful in the context of the investigation. The size of the decrease of the Kaplan-Meier survival estimate S(t) at time t if one extra event should occur is considered in two ways. In the first approach, the investigator sets a maximum acceptable absolute decrease in S(t) should one extra event occur. In the second, a minimum acceptable number of subjects still at risk is calculated by comparing the size of the decrease in S(t) if an extra event should occur with the variability of the survival estimate had all subjects been followed to that time (confidence interval approach). We recommend calculating both limits for the number still at risk and then making an informed choice in the context of the particular investigation. We explore further how the amount of information actually available can assist in considering issues of data maturity for studies whose outcome of interest is a survival percentage at a particular time point. We illustrate the approaches with a number of published studies having differing sample sizes and censoring issues. In particular, one study was the subject of some controversy regarding how far in time the Kaplan-Meier plot should be extended. The proposed methods allow for limits to be calculated simply using the output provided by most statistical packages.
© The Author(s) 2018; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.

Keywords:  Kaplan-Meier curve; data maturity; data presentation; follow-up; number at risk; percentage of actual information available; sensitivity index; time-to-event

Year:  2018        PMID: 29444326     DOI: 10.1093/ije/dyy013

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  10 in total

1.  Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study.

Authors:  Okyaz Eminaga; Eugene Shkolyar; Bernhard Breil; Axel Semjonow; Martin Boegemann; Lei Xing; Ilker Tinay; Joseph C Liao
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

2.  Assessing the Impact of Primary Tumour Location on Survival After Resection of Colorectal Liver Metastases: A Propensity Weighted Retrospective Cohort Study.

Authors:  Aditya Borakati; Farid Froghi; Alysha Shetye; Giuseppe K Fusai; Brian R Davidson; Reza Mirnezami
Journal:  World J Surg       Date:  2022-03-24       Impact factor: 3.282

3.  Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.

Authors:  Kazuhiro Yoshida; Yasuhiro Kodera; Mitsugu Kochi; Wataru Ichikawa; Yoshihiro Kakeji; Takeshi Sano; Narutoshi Nagao; Masazumi Takahashi; Akinori Takagane; Takuya Watanabe; Masahide Kaji; Hiroshi Okitsu; Takashi Nomura; Takanori Matsui; Takaki Yoshikawa; Jin Matsuyama; Makoto Yamada; Seiji Ito; Masahiro Takeuchi; Masashi Fujii
Journal:  J Clin Oncol       Date:  2019-03-29       Impact factor: 44.544

4.  Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.

Authors:  Rebekka Duhen; Carmen Ballesteros-Merino; Alexandra K Frye; Eric Tran; Venkatesh Rajamanickam; Shu-Ching Chang; Yoshinobu Koguchi; Carlo B Bifulco; Brady Bernard; Rom S Leidner; Brendan D Curti; Bernard A Fox; Walter J Urba; R Bryan Bell; Andrew D Weinberg
Journal:  Nat Commun       Date:  2021-02-16       Impact factor: 14.919

5.  Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.

Authors:  Thomas Filleron; Marine Bachelier; Julien Mazieres; Maurice Pérol; Nicolas Meyer; Elodie Martin; Fanny Mathevet; Jean-Yves Dauxois; Raphael Porcher; Jean-Pierre Delord
Journal:  JAMA Netw Open       Date:  2021-12-01

6.  Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Authors:  Mariano Provencio; Roberto Serna-Blasco; Ernest Nadal; Amelia Insa; M Rosario García-Campelo; Joaquín Casal Rubio; Manuel Dómine; Margarita Majem; Delvys Rodríguez-Abreu; Alex Martínez-Martí; Javier De Castro Carpeño; Manuel Cobo; Guillermo López Vivanco; Edel Del Barco; Reyes Bernabé Caro; Nuria Viñolas; Isidoro Barneto Aranda; Santiago Viteri; Eva Pereira; Ana Royuela; Virginia Calvo; Javier Martín-López; Francisco García-García; Marta Casarrubios; Fernando Franco; Estela Sánchez-Herrero; Bartomeu Massuti; Alberto Cruz-Bermúdez; Atocha Romero
Journal:  J Clin Oncol       Date:  2022-05-16       Impact factor: 50.717

7.  Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial.

Authors:  Magnus Nilsson; Halla Olafsdottir; Gabriella Alexandersson von Döbeln; Fernanda Villegas; Giovanna Gagliardi; Mats Hellström; Qiao-Li Wang; Hemming Johansson; Val Gebski; Jakob Hedberg; Fredrik Klevebro; Sheraz Markar; Elizabeth Smyth; Pernilla Lagergren; Ghazwan Al-Haidari; Lars Cato Rekstad; Eirik Kjus Aahlin; Bengt Wallner; David Edholm; Jan Johansson; Eva Szabo; John V Reynolds; C S Pramesh; Naveen Mummudi; Amit Joshi; Lorenzo Ferri; Rebecca Ks Wong; Chris O'Callaghan; Jelena Lukovic; Kelvin Kw Chan; Trevor Leong; Andrew Barbour; Mark Smithers; Yin Li; Xiaozheng Kang; Feng-Ming Kong; Yin-Kai Chao; Tom Crosby; Christiane Bruns; Hanneke van Laarhoven; Mark van Berge Henegouwen; Richard van Hillegersberg; Riccardo Rosati; Guillaume Piessen; Giovanni de Manzoni; Florian Lordick
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

8.  Kidney Transplants in Controlled Donation Following Circulatory Death, or Maastricht Type III Donors, With Abdominal Normothermic Regional Perfusion, Optimizing Functional Outcomes.

Authors:  Patricia Ramirez; David Vázquez; Gabriel Rodríguez; Juan José Rubio; Marina Pérez; Jose Maria Portolés; Joaquín Carballido
Journal:  Transplant Direct       Date:  2021-07-16

9.  Dynamic RMST curves for survival analysis in clinical trials.

Authors:  Jason J Z Liao; G Frank Liu; Wen-Chi Wu
Journal:  BMC Med Res Methodol       Date:  2020-08-27       Impact factor: 4.615

10.  Breast-conserving surgery with intraoperative radiotherapy in recurrent breast cancer: the patient's perspective.

Authors:  Constanze Elfgen; U Güth; G Gruber; S Birrer; V Bjelic-Radisic; M Fleisch; C J Tausch
Journal:  Breast Cancer       Date:  2020-06-01       Impact factor: 4.239

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.